Bernadette Connaughton is an independent director who joined our board in November 2019 and is a member of the Audit Committee. She has three decades of experience in global strategic and leadership roles within large pharma. Ms. Connaughton spent her career at Bristol-Myers Squibb (NYSE: BMY), building a consistent track record of achieving sales growth and improving operational models and profitability in the U.S., Europe and Asia. She most recently served as President Intercontinental. In this role, she developed successful, multi-year commercialization strategies for several oncology, virology and immunology products.
Ms. Connaughton currently serves on the Board of Directors of Zealand Pharma A/S (Nasdaq:ZEAL), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, where she serves on the Audit Committee and Halozyme Therapeutics, Inc. (Nasdaq:HALO), a biotechnology company focused on novel biological and drug delivery approaches, where she serves as Chair of the Compensation Committee. She also currently serves on the Board of Directors of Editas Medicine (Nasdaq: EDIT), a gene editing company focused on developing CRISPR medicines, where she serves as Chair of the Organization, Leadership and Compensation Committee and as a member of the Nominating and Corporate Governance Committee. Ms. Connaughton serves on the Board of Trustees of the Boys and Girls Club of Mercer County, New Jersey. She was previously a member of the Board of Directors of Visterra, Inc. She received her Bachelor of Arts from Johns Hopkins University and her Master of Business Administration from The Wharton School, University of Pennsylvania.